1. Introduction

Artificial placenta governance refers to the legal, ethical, medical, and regulatory framework governing the development, testing, approval, clinical use, and monitoring of technologies designed to support fetal development outside the human uterus.

An artificial placenta system seeks to replicate some functions of the placenta and uterine environment, particularly oxygenation, circulation, and fluid-based support. Experimental systems may help extremely premature infants continue developing in a protected environment. However, a system that supports an already-delivered premature infant is not necessarily equivalent to a technology that sustains an embryo or fetus throughout pregnancy.

The legal significance lies in the fact that this technology challenges established boundaries between pregnancy, childbirth, neonatal intensive care, reproductive autonomy, parental authority, medical experimentation, and the legal status of the developing human.

Important legal qualification: “Artificial Placenta Governance” is an analytical term, not a universally recognised, standalone legal doctrine. The cases discussed below provide relevant principles from medical law, reproductive rights, research ethics, product liability, and human dignity. They should not be mistaken for judgments directly deciding the legality of a fully artificial human placenta.

2. Meaning and scope of governance

Artificial placenta governance concerns six interconnected areas:

Research governance: Whether preclinical and clinical studies are scientifically justified, independently reviewed, and ethically acceptable.

Clinical approval: Whether a device is sufficiently safe and effective for its intended use.

Consent and autonomy: Who may authorise treatment, and how the pregnant patient’s rights interact with the interests of the fetus or newborn.

Legal status: Whether the individual receiving artificial-placenta support is legally treated as a fetus, a newborn, a patient, or another category under the applicable law.

Accountability: Who bears responsibility when a device fails or causes injury.

Access and oversight: How regulators address unequal access, long-term monitoring, data protection, and commercial conflicts of interest.

The central legal challenge is to encourage potentially beneficial medical innovation without treating pregnant patients, fetuses, or newborns merely as instruments of experimentation.

3. Scientific and legal background

Artificial placenta technology is being developed primarily as a potential alternative to conventional neonatal intensive care for extremely premature infants. Research has demonstrated promising results in animal models, but those results do not establish safety or effectiveness in humans. A 2025 systematic review of preclinical evidence identified continuing challenges, including thrombosis, bleeding, infection, and circulatory instability.

PMC

+1

Three distinct applications should be separated:

A. Artificial placenta for extreme prematurity

Closest to the anticipated initial clinical application.

Supports a premature infant after delivery while attempting to preserve aspects of fetal physiology. Regulation would primarily concern neonatal treatment, medical devices, research ethics, and parental consent.

B. Partial ectogestation

Transfers support from the uterus to an external system for part of gestation. It raises difficult questions about birth, legal status, treatment decisions, and the relationship between reproductive autonomy and fetal interests.

C. Complete ectogenesis

A more extensive and distinct technological proposal.

Would involve supporting development from an embryo through gestation outside a human body. This raises additional embryo-research, reproductive, and licensing questions and should not be treated as equivalent to neonatal artificial-placenta support.

The distinctions matter because a legal framework designed for treating a newborn cannot automatically answer questions about an embryo, the termination of pregnancy, or the possibility of transferring a fetus from a pregnant person into an artificial environment.

4. Principal legal principles

4.1 Medical safety and the precautionary principle

An artificial placenta would involve a complex interaction between medical devices, vascular access, fluid environments, monitoring equipment, and potentially life-sustaining interventions. Regulators would need evidence about both immediate safety and longer-term developmental outcomes.

A responsible approval system should require:

Preclinical evidence sufficient to justify the proposed human study.

Independent scientific and research-ethics review.

Clearly defined inclusion and exclusion criteria.

Monitoring and stopping rules for serious adverse events.

A justified comparison with available standard care.

Long-term developmental follow-up, subject to appropriate consent and privacy protections.

The precautionary principle does not necessarily require prohibiting all experimental use. It requires proportionate safeguards where serious risks remain uncertain.

4.2 Informed consent and reproductive autonomy

Consent is one of the most difficult governance questions. An extremely premature infant cannot consent, and parents may be required to make decisions during a medical emergency.

The legal framework must distinguish between:

A parent's permission for clinically indicated treatment.

A parent's permission for a research intervention that may not directly benefit the child.

The pregnant patient's independent decisions about medical care and pregnancy.

Consent for the use of embryos or reproductive material in research.

Permission for ordinary treatment does not automatically constitute permission for experimental research. Researchers must explain the uncertainty, foreseeable risks, alternatives, and the distinction between treatment and research.

4.3 Legal personhood and the status of the patient

An individual supported by an artificial placenta may retain fetal physiology while being physically outside the uterus. This creates uncertainty about which legal rules should apply.

Potential issues include:

When legal personhood begins under the relevant jurisdiction.

Whether birth-related registration and death-certification rules apply.

Who may make medical decisions for the patient.

How best interests are assessed.

Whether withdrawing artificial-placenta support is governed by neonatal end-of-life law.

The 2025 literature on defining the threshold of birth argues that medical innovation must not itself diminish a patient's personhood. That is an important proposed governance principle, rather than a universally established judicial rule.

PubMed

+1

4.4 Product liability and professional negligence

If an artificial placenta causes harm, responsibility may potentially arise under several legal routes:

Manufacturer liability: defective design, manufacture, software, instructions, or inadequate warnings.

Clinical negligence: failure to meet the applicable professional standard of care.

Institutional liability: inadequate training, staffing, maintenance, or emergency procedures.

Research liability: protocol violations, deficient consent, inadequate monitoring, or failure to report adverse events.

The applicable cause of action depends on the jurisdiction, the patient's legal status, the nature of the injury, and the relationship between the manufacturer, researcher, hospital, and patient.

5. Case laws relevant to artificial placenta governance

The following decisions establish legal principles that could guide courts and regulators. None of the cases listed below directly establishes a comprehensive legal regime for artificial placenta technology.

Case 1: Suchita Srivastava v. Chandigarh Administration (2009)

Supreme Court of India · (2009) 9 SCC 1

Facts and issue: The case concerned a woman with an intellectual disability who was pregnant while residing in a government institution. The question was whether the authorities could terminate her pregnancy without her consent under the circumstances.

Decision: The Supreme Court recognised reproductive choice as an aspect of personal liberty under Article 21 of the Indian Constitution. It emphasised the woman's right to choose whether to continue her pregnancy, subject to the applicable law.

Relevance to artificial placenta governance: This case is important if artificial-placenta technology is proposed as a means of transferring a fetus from a pregnant person to an external system.

A future legal dispute might ask whether a pregnant person could be compelled to undergo a procedure intended to facilitate artificial gestation because it is considered beneficial to the fetus. The principle of reproductive autonomy weighs against assuming that a technological alternative automatically overrides the pregnant person's bodily integrity or lawful reproductive choices.

Governance implication: Artificial placenta technology should not be used to create a general legal obligation to undergo invasive medical procedures or to continue a pregnancy against the person's lawful wishes.

Case 2: K.S. Puttaswamy v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Facts and issue: The Supreme Court considered whether privacy is protected as a fundamental right under the Indian Constitution.

Decision: A nine-judge bench unanimously recognised the fundamental right to privacy, grounded in constitutional guarantees including life and personal liberty under Article 21.

Relevance to artificial placenta governance: Artificial-placenta systems may generate sensitive information about fetal development, genetic characteristics, physiological status, and medical outcomes. The collection and secondary use of this information raise privacy and data-governance concerns.

The case supports scrutiny of intrusive collection, use, or disclosure of personal medical information. It does not, by itself, determine the legal ownership or privacy status of every category of fetal data.

Governance implication: Regulators and healthcare institutions should establish rules on data minimisation, access controls, research reuse, security, and disclosure. Any reliance on consent must account for the fact that the developing patient cannot personally provide it.

Case 3: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Facts and issue: The case concerned the limits of a doctor's authority to undertake additional medical procedures when the patient had consented to a particular procedure.

Decision: The Supreme Court explained the requirements of valid medical consent, including adequate information and consent appropriate to the procedure. It distinguished consent to one intervention from consent to a substantially different intervention, subject to recognised emergency exceptions.

Relevance to artificial placenta governance: A parent agreeing to conventional intensive care should not automatically be treated as having agreed to an experimental artificial-placenta intervention. The technology could involve different surgical risks, uncertainty, and monitoring requirements.

Likewise, consent to a research study must not be disguised as consent to routine treatment.

Governance implication: Consent documents should explain the nature of the intervention, alternatives, material risks, research objectives, and the right to decline research without inappropriate pressure.

Case 4: Jacob Mathew v. State of Punjab (2005)

Supreme Court of India · (2005) 6 SCC 1

Facts and issue: The case concerned criminal liability for alleged medical negligence and the standards required to establish such liability.

Decision: The Supreme Court examined the distinction between civil negligence and criminal medical negligence. Criminal liability requires a sufficiently high degree of negligence; an adverse outcome alone is not proof of criminal culpability.

Relevance to artificial placenta governance: Suppose a device fails to maintain adequate oxygenation and the infant suffers injury. The legal analysis would require investigation into the circumstances, including whether the device malfunctioned, whether clinicians followed appropriate protocols, and whether the applicable standard of care was breached.

The experimental nature of a device would not automatically establish negligence, but neither would innovation provide immunity from liability.

Governance implication: Clear clinical protocols, training, adverse-event reporting, equipment maintenance, and documentation are essential. Courts should distinguish unavoidable complications from negligent conduct and product defects.

Case 5: Common Cause v. Union of India (2018)

Supreme Court of India · (2018) 5 SCC 1

Facts and issue: The case addressed passive euthanasia and the legal recognition of advance directives in specified circumstances.

Decision: The Supreme Court recognised the constitutional significance of dignity and autonomy at the end of life and established safeguards for withdrawing life-sustaining treatment in appropriate cases. The legal framework has subsequently been subject to further judicial clarification.

Relevance to artificial placenta governance: Artificial-placenta treatment may involve continuing life-sustaining support where prognosis is uncertain or complications become severe. Questions may arise about whether treatment should continue, whether it is medically futile, and how the patient's best interests should be assessed.

However, decisions about withdrawing support from a premature infant cannot simply be equated with advance directives made by a competent adult. Separate rules governing children, parental authority, and best interests remain important.

Governance implication: Clinical guidelines should establish procedures for prognosis review, multidisciplinary consultation, parental communication, dispute resolution, and lawful withdrawal of treatment.

Case 6: Montgomery v. Lanarkshire Health Board (2015)

UK Supreme Court · [2015] UKSC 11

Facts: A pregnant woman with diabetes was not adequately informed of the risk of shoulder dystocia during vaginal delivery or of the alternative of a caesarean section.

Decision: The Supreme Court held that doctors must take reasonable care to inform patients about material risks and reasonable alternative treatments.

UK Supreme Court

+1

Relevance: Artificial-placenta procedures may involve significant risks and alternatives, including conventional neonatal care. This case supports transparent disclosure rather than allowing medical professionals to decide unilaterally which risks patients should know.

Governance implication: Consent discussions should cover the uncertainties of the technology, the possible consequences of transferring the infant to the system, alternative treatment options, and the possibility that the intervention may fail.

The case directly concerns informed consent under UK law; its application to artificial-placenta treatment is an analogy, not a specific judicial ruling on the technology.

Case 7: Evans v. United Kingdom (2007)

European Court of Human Rights, Grand Chamber · Application No. 6339/05

Facts: The case concerned the use of embryos created through in-vitro fertilisation after one genetic contributor withdrew consent.

Decision: The Court found no violation of Article 8 of the European Convention on Human Rights in the application of the UK's continuing-consent requirements. It emphasised the sensitive ethical questions and the latitude available to states in this area.

HUDOC

+1

Relevance: Artificial placenta technology could eventually intersect with embryo research, reproductive material, and decisions about continued gestation. The case illustrates the importance of clear consent rules and legal certainty in reproductive medicine.

Governance implication: Legislatures should establish explicit rules concerning consent, withdrawal of consent, embryo research, and the limits of parental or genetic-contributor authority. The case does not decide whether consent may be withdrawn after an artificial placenta has begun sustaining a fetus.

Case 8: Parrillo v. Italy (2015)

European Court of Human Rights, Grand Chamber · Application No. 46470/11

Facts: The applicant challenged Italy's prohibition on donating embryos created through IVF to scientific research.

Decision: The Court found no violation of Article 8 of the European Convention on Human Rights. It recognised the relevance of the applicant's private life but allowed the state a margin of appreciation concerning the ethically sensitive issue of embryo research.

Chamber Judgment

+1

Relevance: Artificial placenta development may involve embryo research or reproductive materials, particularly if the technology expands beyond treating premature infants.

Governance implication: A legal framework must distinguish research intended to develop treatment for premature infants from research involving embryos or complete ectogenesis. The applicable consent and licensing requirements may differ significantly.

6. Artificial placenta governance under Indian law

India does not have a single, dedicated statute establishing a complete artificial-placenta regulatory regime. If the technology is introduced for clinical use or human research, several existing legal frameworks could become relevant.

These laws should not be assumed to cover every artificial-placenta scenario in precisely the same way. The regulatory classification of the particular device, the intended clinical purpose, the type of investigation, and the applicable rules at the time of use must be determined.

Constitutional issues

Article 21 is particularly significant because artificial-placenta technology can affect bodily autonomy, medical decision-making, and the protection of life.

Three competing interests may arise:

The pregnant patient's right to bodily integrity and reproductive choice.

The developing patient's interests in receiving appropriate medical care.

The state's responsibility to regulate potentially dangerous medical innovation.

The legal difficulty is not solved simply by declaring one interest superior in every situation. Decisions must account for the applicable legislation, the patient's circumstances, the nature of the proposed procedure, and the relevant constitutional principles.

7. Major governance challenges

A. Clinical-trial selection

Researchers must identify an ethically defensible participant group, justify why existing treatment is insufficient, and establish stopping criteria. Parents should not be led to believe that an experimental intervention is proven treatment.

B. Best interests and parental authority

Parents generally play a central role in decisions for infants, but their authority is not unlimited. Decisions must comply with the relevant law and protect the child's welfare.

C. Withdrawal of life-sustaining support

A system may sustain physiological functions without guaranteeing recovery. Governance must address prognosis, treatment burdens, clinical disagreement, and lawful end-of-life decisions.

D. Equity and reproductive pressure

Access should not depend solely on wealth or institutional resources. Nor should the availability of artificial gestation create an automatic expectation that a pregnant person must undergo a procedure or that a particular reproductive choice must be made.

E. Long-term accountability

Post-treatment surveillance, developmental follow-up, adverse-event reporting, independent audits, and transparent publication of trial outcomes are necessary to assess risks that may not be apparent during initial treatment.

A systematic review published in 2025 found that the artificial-placenta ethics literature has devoted substantial attention to abortion and complete artificial gestation, sometimes at the expense of the technology's nearer-term potential application to extremely premature infants. Governance should therefore be proportionate to the actual intended use, rather than treating every proposed application as identical.

PubMed

+1

8. A proposed model for artificial placenta governance

A workable framework could contain the following stages.

01

Preclinical assessment

Demonstrate sufficient evidence from laboratory and animal research, including physiological stability and relevant organ-development outcomes.

02

Independent authorisation

Require appropriate regulatory approval, research-ethics review, and a scientifically defensible trial protocol.

03

Consent and participant protection

Provide clear information, establish parental decision-making safeguards, and separately protect the pregnant patient's autonomy.

04

Controlled clinical introduction

Use staged trials, independent safety monitoring, predetermined stopping rules, and justified comparisons with standard care.

05

Continuing oversight

Monitor device performance, developmental outcomes, adverse events, data security, and equitable access.

This model is a proposed governance framework, not a description of a single existing statutory procedure. The details must be adapted to the applicable jurisdiction and regulatory classification.

9. Critical legal questions for future courts

As the technology develops, courts may be required to address questions that existing precedents do not fully resolve.

Wrongful death: How should death be legally characterised when an individual is sustained by an artificial placenta rather than conventional neonatal equipment?

Medical negligence: What standard of care applies when a clinician chooses between conventional intensive care and an experimental artificial-placenta system?

Withdrawal of support: Who has authority to decide when continued artificial-placenta treatment is no longer in the patient's best interests?

Reproductive autonomy: Can a person be required to undergo a procedure intended to transfer gestation to an external system?

Legal personhood: Does the applicable law classify the patient by physiological development, the fact of birth, or another legally relevant criterion?

Manufacturer accountability: How should responsibility be divided among the device manufacturer, software developer, clinical team, and hospital?

These questions should be answered through legislation, regulatory standards, and carefully reasoned judicial decisions rather than through assumptions that artificial gestation must be treated identically to conventional pregnancy or neonatal care.

10. Conclusion

Artificial placenta governance is an emerging field at the intersection of reproductive law, medical-device regulation, bioethics, constitutional rights, and clinical negligence.

The Indian decisions in Suchita Srivastava, K.S. Puttaswamy, Samira Kohli, Jacob Mathew, and Common Cause provide important principles concerning reproductive autonomy, privacy, informed consent, professional responsibility, and end-of-life decisions. The UK decision in Montgomery and the European Court's decisions in Evans and Parrillo offer further comparative perspectives on consent, reproductive material, and ethically sensitive biomedical regulation.

The key principle is that technological innovation must not displace established protections for bodily autonomy, patient welfare, informed decision-making, and accountability. At the same time, regulation should distinguish realistic treatment applications for extremely premature infants from more speculative proposals for complete artificial gestation.

The appropriate legal response is a staged, evidence-based, and rights-respecting framework that allows scientific progress while maintaining independent oversight and clear responsibility for harm.

Research note: The case-law analysis above is current to the sources consulted for this response. The cited judgments are analogous precedents, not direct judicial determinations of artificial-placenta technology. For formal legal research, the latest statutory text, applicable regulations, and subsequent judicial treatment should be verified before relying on the analysis in litigation or publication.